Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.
BACKGROUND
Selective cyclooxygenase (COX)-2 inhibitors elicit anti-proliferative responses in various tumours, however the underlying anti-tumour mechanisms are unclear. Mutational inactivation of the tumour suppressor p53 gene is frequent in malignant gliomas. The role of p53 mutation in the anti-tumour responses of the selective COX-2 inhibitor celecoxib in human glioblastoma cells is unknown. In this study, we used human glioblastoma cells with various p53 status; U87MG (with high and low p53 functional levels), LN229 (functional p53) and U373MG (mutant p53) cells. Inhibition of p53 was achieved in U87MG cells transfected with E6 oncoprotein (U87MG-E6) and treated with pifithrin-alpha, a reversible inhibitor of p53 (U87MG-PFT). We investigated whether the anti-glioblastoma responses of celecoxib were p53-dependent, and whether celecoxib induced DNA damage leading to p53-dependent G1 cell cycle arrest, followed by autophagy or apoptosis.


RESULTS
Our findings demonstrated that celecoxib concentration-dependently reduced glioblastoma cell viability, following 24 and 72 hours of treatment. Inhibition of functional p53 in glioblastoma cells significantly reduced the anti-proliferative effect of celecoxib. In U87MG cells, celecoxib (8 and 30 muM) significantly induced DNA damage and inhibited DNA synthesis, corresponding with p53 activation. Celecoxib induced G1-phase cell cycle arrest, accompanied with p21 activation in U87MG cells. Cell cycle progression of U87MG-E6 and U87MG-PFT cells was not affected by celecoxib. In parallel, celecoxib induced G1 cell cycle arrest in LN229 cells, but not in U373MG cells. Autophagy was induced by celecoxib in U87MG and LN229 cells, as shown by the significantly greater population of acridine orange-stained cells and increased levels of LC3-II protein (in comparison with non-treated controls). Celecoxib did not induce significant autophagy in U87MG-PFT, U87MG-E6 and U373MG cells, which lack functional p53. Regardless of p53 status, celecoxib caused no significant difference in apoptosis level of U87MG, U87MG-PFT, U87MG-E6 and U373MG cells.


CONCLUSIONS
Our findings reveal that p53 increases human glioblastoma sensitivity to celecoxib. Celecoxib inhibits glioblastoma cell viability by induction of DNA damage, leading to p53-dependent G1 cell cycle arrest and p53-dependent autophagy, but not apoptosis.
Kang
Khong Bee
KB
Brain Tumour Research Laboratory, Division of Medical Sciences, Humphrey Oei Institute of Cancer Research, National Cancer Centre, 11 Hospital Drive, 169610, Singapore. dmskkb@nccs.com.sg
Zhu
Congju
C
Yong
Sook Kwin
SK
Gao
Qiuhan
Q
Wong
Meng Cheong
MC
D000704:Analysis of Variance; D001343:Autophagy / Q000187:drug effects*; D052160:Benzothiazoles / Q000494:pharmacology; D015153:Blotting, Western; D000068579:Celecoxib; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D020552:Comet Assay; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004249:DNA Damage; D004305:Dose-Response Relationship, Drug; D016193:G1 Phase / Q000187:drug effects*; D006801:Humans; D007150:Immunohistochemistry; D011720:Pyrazoles / Q000494:pharmacology*; D016192:Resting Phase, Cell Cycle / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000494:pharmacology*; D014050:Toluene / Q000031:analogs & derivatives / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
D052160:Benzothiazoles; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D016159:Tumor Suppressor Protein p53; D014050:Toluene; C121565:pifithrin; D000068579:Celecoxib
Cell. 1997 Feb 7;88(3):323-31
9039259
Acta Neuropathol. 1999 Sep;98(3):240-4
10483780
Biochem Pharmacol. 1998 Jan 1;55(1):53-64
9413930
Science. 2000 Dec 1;290(5497):1717-21
11099404
Apoptosis. 2007 Jan;12(1):195-209
17136320
J Biol Chem. 2005 Aug 5;280(31):28337-46
15964853
Cancer Res. 2003 Sep 1;63(17):5239-42
14500353
Cancer Res. 2007 Dec 15;67(24):11886-95
18089819
Int J Cancer. 2005 Aug 20;116(2):187-92
15800902
J Exp Med. 1999 Aug 16;190(4):445-50
10449515
Cancer Res. 1998 Sep 1;58(17):3761-4
9731479
J Biol Chem. 2002 Aug 2;277(31):27613-21
12000750
Biochem Pharmacol. 2009 Jul 1;78(1):21-32
19447220
Biochem Pharmacol. 2005 Mar 1;69(5):831-9
15710360
J Neurosurg. 2003 Feb;98(2):378-84
12593626
Nat Cell Biol. 2008 Jun;10(6):637-9
18521069
Cancer Res. 2000 Sep 1;60(17):4926-31
10987308
Eur J Clin Invest. 2003 Oct;33(10):875-82
14511359
Clin Cancer Res. 2007 Feb 15;13(4):1315-21
17317843
J Neurooncol. 2006 May;78(1):85-90
16391896
Eur J Cancer. 2006 Feb;42(3):422-6
16426843
Cancer Res. 1990 Aug 1;50(15):4473-7
2369725
Biochem Biophys Res Commun. 2002 May 3;293(2):705-9
12054526
Carcinogenesis. 2000 May;21(5):973-6
10783320
Oncol Rep. 2004 Feb;11(2):263-8
14719052
Cancer Res. 2001 Jan 15;61(2):439-44
11212227
Acta Neuropathol. 2001 Aug;102(2):181-7
11563634
Oncogene. 2004 Mar 25;23(13):2305-14
14743207
Cancer Res. 2006 Oct 1;66(19):9349-51
17018585
Cancer Res. 2001 Jun 1;61(11):4375-81
11389063
Brain Pathol. 1993 Jul;3(3):229-35
8293182
Cancer Res. 2001 May 15;61(10):4155-9
11358839
Cancer Res. 2000 Mar 1;60(5):1306-11
10728691
FASEB J. 2001 Dec;15(14):2742-4
11606477
Cancer Res. 1994 Mar 1;54(5):1169-74
8118801
Biochem J. 1988 Apr 15;251(2):483-90
2840897
J Biol Chem. 1999 Aug 13;274(33):22903-6
10438452
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9
15928081
Clin Cancer Res. 2000 Jun;6(6):2513-20
10873107
Biochemistry (Mosc). 2000 Jan;65(1):41-8
10702639
Clin Cancer Res. 2003 Aug 15;9(9):3503-13
12960143
Anticancer Res. 2006 Nov-Dec;26(6B):4245-54
17201140
Biochem Pharmacol. 2004 Apr 15;67(8):1469-78
15041464
Anticancer Res. 2006 May-Jun;26(3A):2003-7
16827136
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):888-96
17293239
Cell. 2006 Jul 14;126(1):121-34
16839881
Oncogene. 2004 Apr 12;23(16):2797-808
15077143
EMBO J. 2000 Nov 1;19(21):5720-8
11060023
Cancer Res. 2004 Feb 15;64(4):1369-76
14973068
Cancer Biol Ther. 2004 Jan;3(1):55-62
14726653
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7
9874808
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Am J Clin Oncol. 2003 Aug;26(4):S103-9
12902866
Neuro Oncol. 2002 Jan;4(1):22-5
11772429
Cancer Immunol Immunother. 2008 Mar;57(3):347-58
17668203
Mol Cancer. 2006 May 18;5:19
16707021